Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 248

1.

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.

Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C, Anderson KC, Weller E, Trippa L, Shain K, Richardson PG.

Am J Hematol. 2019 Nov;94(11):1244-1253. doi: 10.1002/ajh.25627. Epub 2019 Oct 4.

PMID:
31456261
2.

Immunotherapy for hematological malignancies.

Dong S, Ghobrial IM.

J Life Sci (Westlake Village). 2019 Jun;1(1):46-52.

3.

Reply to F.D. Leonard.

Bustoros M, Sklavenitis-Pistofidis R, Castillo JJ, Treon SP, Ghobrial IM.

J Clin Oncol. 2019 Oct 10;37(29):2701-2702. doi: 10.1200/JCO.19.01708. Epub 2019 Aug 19. No abstract available.

PMID:
31424980
4.

Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.

Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S.

Ann Oncol. 2019 Aug 13. pii: mdz218. doi: 10.1093/annonc/mdz218. [Epub ahead of print] No abstract available.

PMID:
31406996
5.

Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia.

Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP.

Clin Cancer Res. 2019 Aug 1;25(15):4860. doi: 10.1158/1078-0432.CCR-19-2051. No abstract available.

PMID:
31371310
6.

Author Correction: Mitochondrial metabolism promotes adaptation to proteotoxic stress.

Tsvetkov P, Detappe A, Cai K, Keys HR, Brune Z, Ying W, Thiru P, Reidy M, Kugener G, Rossen J, Kocak M, Kory N, Tsherniak A, Santagata S, Whitesell L, Ghobrial IM, Markley JL, Lindquist S, Golub TR.

Nat Chem Biol. 2019 Jul;15(7):757. doi: 10.1038/s41589-019-0315-5.

PMID:
31164776
7.

Dietary Pattern and Risk of Multiple Myeloma in Two Large Prospective US Cohort Studies.

Lee DH, Fung TT, Tabung FK, Colditz GA, Ghobrial IM, Rosner BA, Giovannucci EL, Birmann BM.

JNCI Cancer Spectr. 2019 Jun;3(2):pkz025. doi: 10.1093/jncics/pkz025. Epub 2019 Apr 27.

8.

A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.

Ghobrial IM, Vij R, Siegel D, Badros A, Kaufman J, Raje N, Jakubowiak A, Savona MR, Obreja M, Berdeja JG.

Clin Cancer Res. 2019 Aug 15;25(16):4907-4916. doi: 10.1158/1078-0432.CCR-18-3728. Epub 2019 May 29.

PMID:
31142508
9.

Mitochondrial metabolism promotes adaptation to proteotoxic stress.

Tsvetkov P, Detappe A, Cai K, Keys HR, Brune Z, Ying W, Thiru P, Reidy M, Kugener G, Rossen J, Kocak M, Kory N, Tsherniak A, Santagata S, Whitesell L, Ghobrial IM, Markley JL, Lindquist S, Golub TR.

Nat Chem Biol. 2019 Jul;15(7):681-689. doi: 10.1038/s41589-019-0291-9. Epub 2019 May 27. Erratum in: Nat Chem Biol. 2019 Jun 4;:.

PMID:
31133756
10.

Monoclonal gammopathy of undetermined significance.

Mouhieddine TH, Weeks LD, Ghobrial IM.

Blood. 2019 Jun 6;133(23):2484-2494. doi: 10.1182/blood.2019846782. Epub 2019 Apr 22. Review.

PMID:
31010848
11.

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.

Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM.

J Clin Oncol. 2019 Jun 1;37(16):1403-1411. doi: 10.1200/JCO.19.00394. Epub 2019 Apr 16.

PMID:
30990729
12.

Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma.

Sahin I, Kawano Y, Sklavenitis-Pistofidis R, Moschetta M, Mishima Y, Manier S, Sacco A, Carrasco R, Fonseca R, Roccaro AM, Witzig T, Ghobrial IM.

Blood Adv. 2019 Apr 9;3(7):995-1002. doi: 10.1182/bloodadvances.2018028456.

13.

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.

Bustoros M, Kastritis E, Sklavenitis-Pistofidis R, Liu CJ, Hornburg K, Kanellias N, Kim G, Liu D, Gavriatopoulou M, Marinac CR, Roussou M, Migkou M, Noonan K, Reyes K, Rivotto B, Neuse CJ, Ziogas DC, Laubach J, Terpos E, Anderson KC, Richardson PG, Ghobrial IM, Dimopoulos MA.

Am J Hematol. 2019 May;94(5):E146-E149. doi: 10.1002/ajh.25441. Epub 2019 Mar 6. No abstract available.

PMID:
30773670
14.

Autologous graft versus myeloma: it's not a myth.

Dong S, Ghobrial IM.

J Clin Invest. 2019 Jan 2;129(1):48-50. doi: 10.1172/JCI125431. Epub 2018 Nov 19.

15.

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.

Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, Reidy M, Zavidij O, Huynh D, Henrick P, Savell A, Reyes K, Rivotto B, Bustoros M, Perilla-Glen A, Trippa L, Castillo JJ, Treon SP, Ghobrial IM.

Blood. 2018 Dec 13;132(24):2608-2612. doi: 10.1182/blood-2018-07-863241. Epub 2018 Oct 26. No abstract available.

PMID:
30366921
16.

Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia.

Bouyssou JM, Liu CJ, Bustoros M, Sklavenitis-Pistofidis R, Aljawai Y, Manier S, Yosef A, Sacco A, Kokubun K, Tsukamoto S, Perilla Glen A, Huynh D, Castillo JJ, Treon SP, Leblond V, Hermine O, Roccaro AM, Ghobrial IM, Capelletti M.

PLoS One. 2018 Oct 4;13(10):e0204589. doi: 10.1371/journal.pone.0204589. eCollection 2018.

17.

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.

Laubach JP, Liu CJ, Raje NS, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Hedlund J, Martin M, Reynolds C, Shain KH, Zackon I, Stampleman L, Henrick P, Rivotto B, Hornburg KTV, Dumke HJ, Chuma S, Savell A, Handisides DR, Kroll S, Anderson KC, Richardson PG, Ghobrial IM.

Clin Cancer Res. 2019 Jan 15;25(2):478-486. doi: 10.1158/1078-0432.CCR-18-1325. Epub 2018 Oct 2.

PMID:
30279233
18.

Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.

Aldoss I, Capelletti M, Park J, Pistofidis RS, Pillai R, Stiller T, Sanchez JF, Forman SJ, Ghobrial IM, Krishnan A.

Leukemia. 2019 Jan;33(1):266-270. doi: 10.1038/s41375-018-0213-y. Epub 2018 Jul 19.

PMID:
30026571
19.

Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche.

Tsukamoto S, Løvendorf MB, Park J, Salem KZ, Reagan MR, Manier S, Zavidij O, Rahmat M, Huynh D, Takagi S, Kawano Y, Kokubun K, Thrue CA, Nagano K, Petri A, Roccaro AM, Capelletti M, Baron R, Kauppinen S, Ghobrial IM.

Leukemia. 2018 Aug;32(8):1739-1750. doi: 10.1038/s41375-018-0161-6. Epub 2018 Jun 20.

PMID:
29925904
20.

Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation.

Cheng MP, Pandit A, Antin JH, Walsh SR, Huynh D, Ghobrial IM, Baden LR, Marty FM, Issa NC.

Blood Adv. 2018 Jun 12;2(11):1272-1276. doi: 10.1182/bloodadvances.2018018911. Erratum in: Blood Adv. 2018 Jul 10;2(13):1541.

21.

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.

O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS.

Br J Haematol. 2018 Jul;182(2):222-230. doi: 10.1111/bjh.15261. Epub 2018 May 8.

22.

Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.

Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, Rhoades J, Liu CJ, Huynh D, Reed SC, Gydush G, Salem KZ, Rotem D, Freymond C, Yosef A, Perilla-Glen A, Garderet L, Van Allen EM, Kumar S, Love JC, Getz G, Adalsteinsson VA, Ghobrial IM.

Nat Commun. 2018 Apr 27;9(1):1691. doi: 10.1038/s41467-018-04001-5.

23.

Current use of monoclonal antibodies in the treatment of multiple myeloma.

Varga C, Maglio M, Ghobrial IM, Richardson PG.

Br J Haematol. 2018 May;181(4):447-459. doi: 10.1111/bjh.15121. Epub 2018 Apr 25. Review.

PMID:
29696629
24.

Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.

Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, Moschetta M, Mishima Y, Roccaro A, Detappe A, Liu CJ, Sacco A, Huynh D, Tai YT, Robbins MD, Azzi J, Ghobrial IM.

Mol Cancer Ther. 2018 Jul;17(7):1454-1463. doi: 10.1158/1535-7163.MCT-17-0998. Epub 2018 Apr 13.

25.

Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine TH, Manier S, Mishima Y, Murakami N, Bustoros M, Pistofidis RS, Reidy M, Shen YJ, Rahmat M, Lukyanchykov P, Karreci ES, Tsukamoto S, Shi J, Takagi S, Huynh D, Sacco A, Tai YT, Chesi M, Bergsagel PL, Roccaro AM, Azzi J, Ghobrial IM.

J Clin Invest. 2018 Jun 1;128(6):2487-2499. doi: 10.1172/JCI88169. Epub 2018 May 14.

26.

Targeting MYC in multiple myeloma.

Jovanović KK, Roche-Lestienne C, Ghobrial IM, Facon T, Quesnel B, Manier S.

Leukemia. 2018 Jun;32(6):1295-1306. doi: 10.1038/s41375-018-0036-x. Epub 2018 Feb 22. Review.

PMID:
29467490
27.

Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation.

Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M, Liu CJ, Mishima Y, Kokubun K, Manier S, Salem KZ, Huynh D, Sacco A, Forward J, Roccaro AM, Battinelli EM, Ghobrial IM.

Clin Cancer Res. 2018 May 15;24(10):2430-2439. doi: 10.1158/1078-0432.CCR-17-2003. Epub 2018 Feb 9.

28.

The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Ghobrial IM, Detappe A, Anderson KC, Steensma DP.

Nat Rev Clin Oncol. 2018 Apr;15(4):219-233. doi: 10.1038/nrclinonc.2017.197. Epub 2018 Jan 9. Review.

PMID:
29311715
29.

Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice.

Bornstein S, Moschetta M, Kawano Y, Sacco A, Huynh D, Brooks D, Manier S, Fairfield H, Falank C, Roccaro AM, Nagano K, Baron R, Bouxein M, Vary C, Ghobrial IM, Rosen CJ, Reagan MR.

Endocrinology. 2017 Oct 1;158(10):3369-3385. doi: 10.1210/en.2017-00299.

30.

Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.

Moschetta M, Kawano Y, Sacco A, Belotti A, Ribolla R, Chiarini M, Giustini V, Bertoli D, Sottini A, Valotti M, Ghidini C, Serana F, Malagola M, Imberti L, Russo D, Montanelli A, Rossi G, Reagan MR, Maiso P, Paiva B, Ghobrial IM, Roccaro AM.

Curr Osteoporos Rep. 2017 Oct;15(5):499-506. doi: 10.1007/s11914-017-0399-3. Review.

PMID:
28889371
31.

Established and Novel Prognostic Biomarkers in Multiple Myeloma.

Bustoros M, Mouhieddine TH, Detappe A, Ghobrial IM.

Am Soc Clin Oncol Educ Book. 2017;37:548-560. doi: 10.14694/EDBK_175175. Review.

PMID:
28561668
32.

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI.

Blood. 2017 Jun 29;129(26):3452-3464. doi: 10.1182/blood-2017-03-773341. Epub 2017 May 17.

33.

Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.

Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, Ebright RY, Shi J, Park J, Glavey SV, Devine WG, Liu CJ, Leleu X, Quesnel B, Roche-Lestienne C, Snyder JK, Brown LE, Gray N, Bradner J, Whitesell L, Porco JA Jr, Ghobrial IM.

Sci Transl Med. 2017 May 10;9(389). pii: eaal2668. doi: 10.1126/scitranslmed.aal2668.

34.

Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia.

Gustine JN, Meid K, Dubeau T, Hunter ZR, Xu L, Yang G, Ghobrial IM, Treon SP, Castillo JJ.

Br J Haematol. 2017 Jun;177(5):717-725. doi: 10.1111/bjh.14743. Epub 2017 May 9.

PMID:
28485115
35.

A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation.

Sacco A, Kawano Y, Moschetta M, Zavidij O, Huynh D, Reagan M, Mishima Y, Manier S, Park J, Morgan E, Takagi S, Wong KK, Carrasco R, Ghobrial IM, Roccaro AM.

Am J Hematol. 2017 Aug;92(8):E138-E145. doi: 10.1002/ajh.24778. Epub 2017 Jun 15.

36.

The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions.

Sacco A, Fenotti A, Affò L, Bazzana S, Russo D, Presta M, Malagola M, Anastasia A, Motta M, Patterson CJ, Rossi G, Imberti L, Treon SP, Ghobrial IM, Roccaro AM.

Oncotarget. 2017 May 23;8(21):35435-35444. doi: 10.18632/oncotarget.16130. Review.

37.

IgM myeloma: A multicenter retrospective study of 134 patients.

Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA.

Am J Hematol. 2017 Aug;92(8):746-751. doi: 10.1002/ajh.24753. Epub 2017 May 26.

38.

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.

Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud M, Perilla-Glen A, Aljawai Y, Huynh D, Roccaro AM, Sacco A, Capelletti M, Detappe A, Alignani D, Anderson KC, Munshi NC, Prosper F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson VA, Michor F, San Miguel JF, Ghobrial IM.

Cell Rep. 2017 Apr 4;19(1):218-224. doi: 10.1016/j.celrep.2017.03.025.

39.

Proteomic characterization of human multiple myeloma bone marrow extracellular matrix.

Glavey SV, Naba A, Manier S, Clauser K, Tahri S, Park J, Reagan MR, Moschetta M, Mishima Y, Gambella M, Rocci A, Sacco A, O'Dwyer ME, Asara JM, Palumbo A, Roccaro AM, Hynes RO, Ghobrial IM.

Leukemia. 2017 Nov;31(11):2426-2434. doi: 10.1038/leu.2017.102. Epub 2017 Mar 27.

PMID:
28344315
40.

Prognostic role of circulating exosomal miRNAs in multiple myeloma.

Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, Roccaro AM, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial IM.

Blood. 2017 Apr 27;129(17):2429-2436. doi: 10.1182/blood-2016-09-742296. Epub 2017 Feb 17.

41.

Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.

Bennani NN, LaPlant BR, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic SN, Nowakowski GS, Macon WR, Reeder CB, Mikhael JR, Northfelt DW, Ghobrial IM, Witzig TE.

Am J Hematol. 2017 May;92(5):448-453. doi: 10.1002/ajh.24671. Epub 2017 Mar 10.

42.

Multiple Myeloma and the Immune Microenvironment.

Kawano Y, Roccaro AM, Ghobrial IM, Azzi J.

Curr Cancer Drug Targets. 2017;17(9):806-818. doi: 10.2174/1568009617666170214102301. Review.

PMID:
28201978
43.

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Bar-Natan M, Stroopinsky D, Luptakova K, Coll MD, Apel A, Rajabi H, Pyzer AR, Palmer K, Reagan MR, Nahas MR, Karp Leaf R, Jain S, Arnason J, Ghobrial IM, Anderson KC, Kufe D, Rosenblatt J, Avigan D.

Br J Haematol. 2017 Mar;176(6):929-938. doi: 10.1111/bjh.14493. Epub 2017 Jan 20.

44.

Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.

Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S.

Ann Oncol. 2017 Mar 1;28(3):468-477. doi: 10.1093/annonc/mdw619. Review.

45.

Exosomes in Tumor Angiogenesis.

Salem KZ, Moschetta M, Sacco A, Imberti L, Rossi G, Ghobrial IM, Manier S, Roccaro AM.

Methods Mol Biol. 2016;1464:25-34.

PMID:
27858353
46.

Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).

Treon SP, Meid K, Tripsas C, Heffner LT, Eradat H, Badros AZ, Xu L, Hunter ZR, Yang G, Patterson CJ, Gustine J, Castillo JJ, Matous J, Ghobrial IM.

Clin Cancer Res. 2017 May 15;23(10):2400-2404. doi: 10.1158/1078-0432.CCR-16-1918. Epub 2016 Nov 11.

47.

Epigenomics in Waldenstrom's macroglobulinaemia.

Sacco A, Fenotti A, Bazzana S, Imberti L, Rossi G, Patterson CJ, Treon SP, Ghobrial IM, Roccaro AM.

Best Pract Res Clin Haematol. 2016 Jun;29(2):156-160. doi: 10.1016/j.beha.2016.08.022. Epub 2016 Sep 25. Review.

PMID:
27825461
48.

Genomic complexity of multiple myeloma and its clinical implications.

Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM.

Nat Rev Clin Oncol. 2017 Feb;14(2):100-113. doi: 10.1038/nrclinonc.2016.122. Epub 2016 Aug 17. Review.

PMID:
27531699
49.

The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma.

Manier S, Powers JT, Sacco A, Glavey SV, Huynh D, Reagan MR, Salem KZ, Moschetta M, Shi J, Mishima Y, Roche-Lestienne C, Leleu X, Roccaro AM, Daley GQ, Ghobrial IM.

Leukemia. 2017 Apr;31(4):853-860. doi: 10.1038/leu.2016.296. Epub 2016 Oct 24.

50.

Epigenetics in Multiple Myeloma.

Glavey SV, Manier S, Sacco A, Salem K, Kawano Y, Bouyssou J, Ghobrial IM, Roccaro AM.

Cancer Treat Res. 2016;169:35-49. Review.

PMID:
27696257

Supplemental Content

Loading ...
Support Center